SPORE IN LUNG CANCER

Summary

Principal Investigator: Stephen Baylin
Affiliation: Johns Hopkins University
Country: USA
Abstract: The Johns Hopkins Lung Cancer SPORE is in its tenth year and continues to have as its goals, the performance of highly translational research to move ideas from the bench to bedside, and vice versa, to provide new means for the prevention of, risk assessment for, early detection of, gauging prognosis of, and therapy for, lung cancers of all types. In these efforts, extensive formal collaboration with other Lung Cancer SPORE'S is often emphasized. The program uses the flexibility of the SPORE funding mechanism to extend projects that continually evolve higher and higher translational potential and curtail those that do not. There is an emphasis on constantly bringing in new concepts and directions in parallel with fully evolving those areas that are headed for ultimate translational verification and even reaching common clinical practice. In terms of research at the highest translational level, including work at the population level, the SPORE is presently emphasizing the second and third projects (a collaborative venture with the Colorado SPORE), which are testing epigenetic molecular markers which appear to have very high promise for the areas of risk assessment, early detection, and gauging of prognosis of lung cancer. The first project, also aimed at predicting lung cancer risk and prognosis, is taking new approaches to develop genetic markers for these purposes. A fourth project is developing new concepts for lung cancer prevention by taking the concepts through pre-clinical models and initial proof of principle studies in high risk individuals. This work is very complementary with participation of the Hopkins SPORE in the consortium chemoprevention trials (Lung Cancer Biomarker Chemoprevention Consortium-LCBCC) with the other Lung Cancer SPORES and with a collaborative trial of Iloprost in collaboration with the Colorado SPORE. The fifth and sixth projects are both aimed at development of novel therapeutic strategies for lung cancer with one exploiting new insights into these diseases derived from study of molecular pathways guiding early lung development and the other exploring inhibition of fatty acid synthesis as a new approach.
Funding Period: 1992-09-30 - 2008-11-30
more information: NIH RePORT

Top Publications

  1. pmc Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    BMC Cancer 10:29. 2010
  2. pmc Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung
    Julien D F Licchesi
    Cancer Biology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Carcinogenesis 29:895-904. 2008
  3. ncbi Selective inhibition of fatty acid synthase for lung cancer treatment
    Hajime Orita
    Department of Pathology and Johns Hopkins Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:7139-45. 2007
  4. pmc Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils
    Rajesh K Thimmulappa
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Antioxid Redox Signal 9:1963-70. 2007
  5. pmc WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer
    Hirohide Yoshikawa
    Department of Epigenetic Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Mol Biol Cell 18:4292-303. 2007
  6. ncbi LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 67:4123-9. 2007
  7. pmc Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum
    S A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Br J Cancer 96:1278-83. 2007
  8. ncbi FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer
    Jae Sung Lee
    Department of Radiology, Johns Hopkins Medical Institutions, 1550 Orleans Street, 492 CRB II, Baltimore, Maryland 21231, USA
    Pharm Res 24:1202-7. 2007
  9. pmc Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
    Craig D Peacock
    Sidney Kimmel Comprehensive Cancer Center and Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 104:4048-53. 2007
  10. pmc Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
    A Jimeno
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231 1000, USA
    Br J Cancer 96:952-9. 2007

Scientific Experts

  • Malcolm V Brock
  • Steven Belinsky
  • E A Engels
  • Guojun Wu
  • George K Acquaah-Mensah
  • Thomas Kensler
  • L Casciola-Rosen
  • Kevin K Divine
  • Aleksander Popel
  • R M Tuder
  • Anju Singh
  • Shyam Biswal
  • Rajesh K Thimmulappa
  • James G Herman
  • Craig D Peacock
  • Stephen B Baylin
  • Hajime Orita
  • Edward Gabrielson
  • Masayuki Yamamoto
  • D Neil Watkins
  • Julien D F Licchesi
  • David Sidransky
  • Tirumalai Rangasamy
  • Yi Zhang
  • Jonathan Coulter
  • Francis P Kuhajda
  • Craig M Hooker
  • Michael A Trush
  • William O Osburn
  • Hannah Lee
  • Jacob E Koskimaki
  • Vincent C Daniel
  • Hariharan Easwaran
  • Vasudev J Bailey
  • Elizabeth Griffiths
  • Tza Huei Wang
  • Walter H Watson
  • William H Westra
  • Jatin K Nagpal
  • Jonathan T Rhodes
  • Wendy L Devereux
  • Ellen Tully
  • Barry Trink
  • Jae Sung Lee
  • A Jimeno
  • Hirohide Yoshikawa
  • Karen T Liby
  • Michael B Sporn
  • Kassim Traore
  • Catherine Scollick
  • Antonio Jimeno
  • Sunil Upadhyay
  • Emi Ota Machida
  • Vikas Misra
  • Mohammad O Hoque
  • Nicole E Benoit
  • Hans Hammers
  • Emmanouil D Karagiannis
  • Benjamin C Tang
  • Roberto Pili
  • Jared S Hierman
  • Ana Navas-Acien
  • Gregory Cosgrove
  • Ping Zhang
  • Charles M Rudin
  • Luigi Marchionni
  • Marion Dorsch
  • Avvaru N Suhasini
  • Guoyu Ling
  • Hetty E Carraway
  • Vasudev Bailey
  • Christopher M Puleo
  • Giovanni Parmigiani
  • Rex Yung
  • Elena Feinstein
  • Aviram Nissan
  • Swetlana Boldin-Adamsky
  • Hagit Ashush
  • Srikanta K Rath
  • Antoun Toubaji
  • Young K Chae
  • George J Netto
  • Steven N Goodman
  • Sana Jadallah
  • Edward A Ratovitski
  • Amanda Blackford
  • Toby Eagle
  • Santanu Dasgupta
  • Fred Bunz
  • Emi O Machida

Detail Information

Publications45

  1. pmc Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    BMC Cancer 10:29. 2010
    ....
  2. pmc Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung
    Julien D F Licchesi
    Cancer Biology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Carcinogenesis 29:895-904. 2008
    ....
  3. ncbi Selective inhibition of fatty acid synthase for lung cancer treatment
    Hajime Orita
    Department of Pathology and Johns Hopkins Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:7139-45. 2007
    ..This study investigated pharmacologic inhibition of FAS using C93, a rationally designed molecule that inhibits FAS activity without affecting fatty acid oxidation in preclinical models of lung cancer...
  4. pmc Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils
    Rajesh K Thimmulappa
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Antioxid Redox Signal 9:1963-70. 2007
    ....
  5. pmc WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer
    Hirohide Yoshikawa
    Department of Epigenetic Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Mol Biol Cell 18:4292-303. 2007
    ..We suggest that FGF switches WNT10B from a negative to a positive cell growth regulator...
  6. ncbi LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 67:4123-9. 2007
    ..Thus, our current study suggests for the first time that lysyl oxidase-like genes can act as tumor suppressor genes and exert their functions through the inhibition of the Ras/ERK signaling pathway in human bladder cancer...
  7. pmc Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum
    S A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Br J Cancer 96:1278-83. 2007
    ..These studies demonstrate that sputum can be used effectively as a surrogate for tumour tissue to predict the methylation status of advanced lung cancer where biopsy is not feasible...
  8. ncbi FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer
    Jae Sung Lee
    Department of Radiology, Johns Hopkins Medical Institutions, 1550 Orleans Street, 492 CRB II, Baltimore, Maryland 21231, USA
    Pharm Res 24:1202-7. 2007
    ..The aim of this study was to use positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) to monitor the effects of the FAS inhibitor C75 on tumor glucose metabolism in a rodent model of human A549 lung cancer...
  9. pmc Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
    Craig D Peacock
    Sidney Kimmel Comprehensive Cancer Center and Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 104:4048-53. 2007
    ..The potential existence of similar relationships in other adult cancers may have important biologic and clinical implications for the study of aberrant Hh signaling...
  10. pmc Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
    A Jimeno
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231 1000, USA
    Br J Cancer 96:952-9. 2007
    ..In conclusion, an mTOR inhibitor showed antitumor activity in EGFR-resistant SCC cell lines. Marked antitumor effects were associated with dual pathway inhibition, which were detected by early FNA biopsies...
  11. doi DNA methylation markers and early recurrence in stage I lung cancer
    Malcolm V Brock
    Johns Hopkins Hospital, Baltimore, USA
    N Engl J Med 358:1118-28. 2008
    ..Despite optimal and early surgical treatment of non-small-cell lung cancer (NSCLC), many patients die of recurrent NSCLC. We investigated the association between gene methylation and recurrence of the tumor...
  12. doi Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors
    Hajime Orita
    Department of Pathology and Johns Hopkins Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Clin Cancer Res 14:2458-64. 2008
    ..Fatty acid synthase (FAS) is overexpressed in lung cancer, and we have investigated the potential use of FAS inhibitors for chemoprevention of lung cancer...
  13. pmc MS-qFRET: a quantum dot-based method for analysis of DNA methylation
    Vasudev J Bailey
    Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    Genome Res 19:1455-61. 2009
    ..The direct application of MS-qFRET on clinical samples offers great promise for its translational use in early cancer diagnosis, prognostic assessment of tumor behavior, as well as monitoring response to therapeutic agents...
  14. pmc A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro
    Vincent C Daniel
    Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 69:3364-73. 2009
    ..Such changes in gene expression may be a common feature of many cancer cell culture systems, with functional implications for the use of such models for preclinical drug development...
  15. pmc DNA methylation analysis on a droplet-in-oil PCR array
    Yi Zhang
    Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
    Lab Chip 9:1059-64. 2009
    ..These results were consistent with standard MSP protocols, yet the simplicity of the droplet-in-oil microfluidic PCR platform provides an easy and efficient tool for DNA methylation analysis in a large-scale arrayed manner...
  16. pmc Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs
    Anju Singh
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 212045, USA
    Free Radic Biol Med 46:376-86. 2009
    ..Thus, Srx1, a key Nrf2-regulated gene, contributes to protection against oxidative injury in the lung...
  17. pmc RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy
    Anju Singh
    Department of Environmental Health Sciences, Division of Toxicology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Cancer Res 68:7975-84. 2008
    ..Thus, targeting Nrf2 activity in lung cancers, particularly those with Keap1 mutations, could be a promising strategy to inhibit tumor growth and circumvent chemoresistance...
  18. pmc Cancer stem cells and the ontogeny of lung cancer
    Craig D Peacock
    The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans St, Rm 546, Baltimore, MD 21231, USA
    J Clin Oncol 26:2883-9. 2008
    ..This review summarizes our understanding of the cellular and molecular mechanisms operating within the putative cancer-initiating cell at the core of lung neoplasia...
  19. pmc Profiling the expression pattern of GPI transamidase complex subunits in human cancer
    Jatin K Nagpal
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 21:979-91. 2008
    ..Collectively, our study defines a trend involving the deregulated expression and the functional contribution of the GPIT subunits in various cancers with potential implications in diagnosis, prognosis and therapeutic intervention...
  20. doi Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung
    Julien D F Licchesi
    Cancer Biology Program at the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:2570-8. 2008
    ....
  21. pmc Ethanol sensitivity: a central role for CREB transcription regulation in the cerebellum
    George K Acquaah-Mensah
    Department of Pharmaceutical Sciences, School of Pharmacy Worcester, Massachusetts College of Pharmacy and Health Sciences, 19 Foster Street, Worcester, MA 01608 1715, USA
    BMC Genomics 7:308. 2006
    ..In this report, the extent to which CREB signalling impacts the differential expression of genes in ILS and ISS mouse cerebella is examined...
  22. pmc Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide
    Rajesh K Thimmulappa
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Biochem Biophys Res Commun 351:883-9. 2006
    ..Activation of Nrf2-dependent compensatory antioxidative pathways by CDDO-Im protects from LPS induced inflammatory response and mortality...
  23. pmc Role of lung maintenance program in the heterogeneity of lung destruction in emphysema
    Rubin M Tuder
    Division of Cardiopulmonary Pathology, Department of Pathology, Ross Research Building, Room 519, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Proc Am Thorac Soc 3:673-9. 2006
    ..As injury prevails during the course of this chronic disease, it leads to a more homogeneous pattern of lung disease...
  24. ncbi C-fos assessment as a marker of anti-epidermal growth factor receptor effect
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 66:2385-90. 2006
    ..In summary, variations in c-fos expression reflect the pharmacologic actions of EGFR inhibitors in in vitro and in vivo models...
  25. ncbi Nested multigene MSP/DHPLC method for analyzing promoter hypermethylation status in clinical samples
    Kevin K Divine
    Lovelace Respiratory Research Institute, Albuquerque, NM 87108 5127, USA
    Biotechniques 40:40, 42, 44 passim. 2006
  26. ncbi Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
    Malcolm V Brock
    Division of Thoracic Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Ann Thorac Surg 80:1241-7. 2005
    ..Deoxyribonucleic acid (DNA) methylation is a robust strategy for detecting cancer early in tissue. We hypothesized that DNA methylation would be more sensitive in diagnosing patients with malignant pleural effusions than cytology...
  27. pmc Somatic mutation and gain of copy number of PIK3CA in human breast cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Breast Cancer Res 7:R609-16. 2005
    ..Even though PIK3CA amplification and somatic mutation have been reported previously in various kinds of human cancers, the genetic change in PIK3CA in human breast cancer has not been clearly identified...
  28. pmc Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice
    Tirumalai Rangasamy
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Exp Med 202:47-59. 2005
    ..Our studies suggest that the responsiveness of Nrf2-directed antioxidant pathways may act as a major determinant of susceptibility to allergen-mediated asthma...
  29. ncbi Colorimetric approach to high-throughput mutation analysis
    Nicole E Benoit
    Johns Hopkins University School of Medicine, Baltimore MD 21205, USA
    Biotechniques 38:635-9. 2005
    ..This assay is straightforward, accurate, inexpensive, and allows for rapid, high-throughput analysis of samples, making it ideal for genomic mutation or polymorphism screening studies in both clinical and research settings...
  30. pmc Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
    Livia Casciola-Rosen
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Exp Med 201:591-601. 2005
    ..Regulating pathways of antigen expression may provide unrecognized therapeutic opportunities in autoimmune diseases...
  31. ncbi DeltaNp63alpha up-regulates the Hsp70 gene in human cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205 2196, USA
    Cancer Res 65:758-66. 2005
    ..Our study provides strong evidence for the physiologic association between DeltaNp63alpha and hsp70 in human cancer, thus further supporting the oncogenic potential of DeltaNp63alpha...
  32. ncbi Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer
    Steven A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM 87108, USA
    Carcinogenesis 26:1481-7. 2005
    ....
  33. ncbi Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort
    Steven A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA
    Cancer Res 66:3338-44. 2006
    ....
  34. ncbi Elevated incidence of lung cancer among HIV-infected individuals
    Eric A Engels
    Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 24:1383-8. 2006
    ..We sought to characterize lung cancer incidence among HIV-infected individuals, examine whether cancer risk was related to HIV-induced immunosuppression, and assess whether the high prevalence of smoking explained elevated risk...
  35. ncbi Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 66:9829-36. 2006
    ..This aberrant growth is mediated, at least partially, by phosphorylation of paxillin, contributing to invasion and progression of breast cancer...
  36. pmc Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer
    Anju Singh
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
    PLoS Med 3:e420. 2006
    ..Increased expression of cellular antioxidants and xenobiotic detoxification enzymes has been implicated in resistance of tumor cells against chemotherapeutic drugs...
  37. ncbi Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway
    Thomas W Kensler
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Annu Rev Pharmacol Toxicol 47:89-116. 2007
    ..This review highlights the key elements in this adaptive response to protection against acute and chronic cell injury provoked by environmental stresses...
  38. pmc Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion
    William O Osburn
    Johns Hopkins University Bloomberg School of Public Health, Department of Environmental Health Sciences, Baltimore, MD, USA
    Arch Biochem Biophys 454:7-15. 2006
    ..Thus the enhanced sensitivity of N0 cells does not reflect basal differences in antioxidative capacity, but rather an impaired ability to mount an adaptive response to sustained oxidative stress...
  39. ncbi Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care
    Malcolm V Brock
    Johns Hopkins Hospital, and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:47-55. 2006
    ..Lung cancer is more common in HIV-infected patients than in the general population. We examined how effectively lung cancer was being diagnosed in our HIV-infected patients...
  40. ncbi LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer
    Sunil Upadhyay
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Cancer Res 66:7870-9. 2006
    ..These results suggest that PEA3 stabilization due to LKB1 inactivation could lead to epithelial/mesenchymal transition and greater lung cancer invasion potential...
  41. pmc Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2
    Anju Singh
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    Am J Respir Cell Mol Biol 35:639-50. 2006
    ..This study shows that GPX2 is the major oxidative stress-inducible cellular GPX isoform in the lungs, and that its basal as well as inducible expression is dependent on Nrf2...
  42. ncbi Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer
    Emi Ota Machida
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Res 66:6210-8. 2006
    ..Thus, hypermethylation of ASC/TMS1 is a marker for late-stage lung cancer and, in sputum, could predict prognosis in patients resected for early-stage disease...
  43. pmc Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
    Rajesh K Thimmulappa
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Clin Invest 116:984-95. 2006
    ..Our study reveals Nrf2 as a novel modifier gene of sepsis that determines survival by mounting an appropriate innate immune response...
  44. ncbi Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come
    Malcolm V Brock
    Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
    J Thorac Cardiovasc Surg 129:64-72. 2005
    ..Although resection is not the standard of care in treating small cell lung cancer, new platinum drugs and modern staging have allowed the role of surgery to be reevaluated...